On May 7, Encysive Pharmaceuticals
- Thelin had just $1 million in sales in its first full quarter on the European market. This is not an encouraging sign for future prospects, and sales must pick up considerably in coming quarters.
- The company achieved regulatory approval for Thelin100mg tablets in Australia and is now seeking reimbursement approval in that country.
- Commercial availability of Thelin was recently announced for PAH in the Republic of Ireland and in The Netherlands.
- Encysive re-initiated a Phase II dose ranging study of TBC3711, Encysive's next-generation, highly selective endothelin A antagonist.
- The most important event for the company occurs next month when the FDA decides whether or not to approve Thelin in the U.S. The company has not had good luck with the FDA in prior attempts to obtain approval for Thelin.
(Figures in thousands, except per-share data.)
Income Statement Highlights
|
Q1 2007 |
Q1 2006 |
Change |
|
|---|---|---|---|
|
Sales |
$5,408 |
$3,561 |
51.9% |
|
Net Profit |
($29,908) |
($29,970) |
N/A |
|
EPS |
($0.49) |
($0.51) |
N/A |
|
Diluted Shares |
61,644 |
58,270 |
5.8% |
Get back to basics with the income statement.
Margin Checkup
|
Q1 2007 |
Q1 2006 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
98.8% |
100.0% |
(1.2) |
|
Operating Margin |
(529.9%) |
(853.6%) |
323.6 |
|
Net Margin |
(553.0%) |
(841.6%) |
288.6 |
Margins are the earnings engine.
Balance Sheet Highlights
|
Assets |
Q1 2007 |
Q1 2006 |
Change |
|---|---|---|---|
|
Cash + ST Invest.* |
$52,689 |
$100,529 |
(47.6%) |
|
Accounts Rec. |
No Data |
No Data |
No Data |
|
Inventory |
No Data |
No Data |
No Data |
|
Liabilities |
Q1 2007 |
Q1 2006 |
Change |
|---|---|---|---|
|
Accounts Payable |
No Data |
No Data |
No Data |
|
Long-Term Debt |
$186,532 |
$130,000 |
43.5% |
The balance sheet reflects the company's health.
Cash Flow Highlights
A statement of cash flows was not provided.
Free cash flow is a Fool's best friend.
Related Foolishness:
Encysive is a Rule Breakers recommendation, while Pfizer is an Inside Value pick.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below. Encysive is a Rule Breakers recommendation.
